EUVIMEDEUVIMED entdecken
Crossref

Discovery and Total Synthesis of Crossiguanipyrazines with Potent Activity Against Mycobacterium tuberculosis

Haowen Zhao iD, Etienne Bickel, Jiaqi Liu, Xiaoli Yang, Michael Dal Molin, Jason Chhen, Shuqin Liu, Haiyan Sui, Xiaoying Bian, Xiaoyi Wei, Jan Rybniker, Uli Kazmaier iD und 1 weitere

Angewandte Chemie International Edition · 2025

DOI: 10.1002/anie.202513977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Haowen Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus E8.1, Saarbrücken, 66123, Germ…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Pyrazines, Antitubercular Agents, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Helmholtz Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB), caused by Mycobacterium tuberculosis , remains one of the most devastating infectious diseases, with rising antimicrobial resistance exacerbating the urgent need for new therapeutic agents. Here, we report the discovery of crossiguanipyrazines A‐I, a rare family of potent anti‐TB alkylpyrazines from the underexplored actinobacterium Crossiella cryophila DSM 44230. Crossiguanipyrazines (CGPs) feature an unusual 3‐methoxyl‐2,5,6‐trialkyl‐pyrazine scaffold with variable hydroxylation and N ‐prenylation. The stereochemistry of CGPs A‐G was determined by Mosher's analysis and electronic circular dichroism spectroscopy. Stable isotope‐labeling revealed a unique biosynthetic origin from arginine and acetate. Inhibition with a cytochrome P450 inhibitor suppressed hydroxylation, while feeding experiments with stable isotope‐labeled CGP I demonstrated its role as a precursor for other CGPs, implicating P450 enzymes in CGP diversification. CGPs C and H exhibited potent anti‐TB activity in the low micromolar range without mammalian cell cytotoxicity, unlike previously reported cytotoxic trialkylpyrazine‐type natural products. Structure‐activity relationship (SAR) studies highlighted the critical roles of hydroxylation and N ‐prenylation in modulating biological activity. Furthermore, we achieved the first total synthesis of CGP I, which validated the chemical structure and provided a foundation for further optimization of this compound class. These findings suggest that CGPs can serve as useful starting points for anti‐TB drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisPyrazinesAntitubercular AgentsDrug DiscoveryMicrobial Sensitivity TestsHumansStructure-Activity RelationshipMolecular StructureCytochrome P-450 Enzyme System

Stichwörter der Autor:innen

Antimicrobial activityMycobacterium tuberculosisNatural productsStructure elucidationTotal synthesis

Substanzen

PyrazinesAntitubercular AgentsCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus E8.1, Saarbrücken, 66123, Germany.
  • Helmholtz International Lab for Anti-Infectives, Helmholtz Centre for Infection Research, Braunschweig, 38124, Germany.
  • Organic Chemistry I, Saarland University, Campus C4.2, Saarbrücken, 66123, Germany.
  • Helmholtz International Lab for Anti-infectives, Shandong University-Helmholtz Institute of Biotechnology, State Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
  • Department I of Internal Medicine, Division of Infectious Diseases, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, 50937, Germany.
  • Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50937, Cologne, Germany.

ORCID-Profile: Haowen Zhao, Uli Kazmaier, Chengzhang Fu

Förderung

  • Helmholtz Association

Zitieren

APA

Zhao, H., Bickel, E., Liu, J., Yang, X., Dal Molin, M., Chhen, J., Liu, S., Sui, H., Bian, X., Wei, X., Rybniker, J., Kazmaier, U., & Fu, C. (2025). Discovery and Total Synthesis of Crossiguanipyrazines with Potent Activity Against Mycobacterium tuberculosis. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202513977

Vancouver

Zhao H, Bickel E, Liu J, Yang X, Dal Molin M, Chhen J, et al. Discovery and Total Synthesis of Crossiguanipyrazines with Potent Activity Against Mycobacterium tuberculosis. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202513977

BibTeX
@article{Zhao2025,
  author = {Zhao, Haowen and Bickel, Etienne and Liu, Jiaqi and Yang, Xiaoli and Dal Molin, Michael and Chhen, Jason and Liu, Shuqin and Sui, Haiyan and Bian, Xiaoying and Wei, Xiaoyi and Rybniker, Jan and Kazmaier, Uli and Fu, Chengzhang},
  title = {Discovery and Total Synthesis of Crossiguanipyrazines with Potent Activity Against Mycobacterium tuberculosis},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  doi = {10.1002/anie.202513977}
}
Kostenlos starten →